Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Amortizatization of Intangibles (2020 - 2025)

Cue Biopharma's Amortizatization of Intangibles history spans 4 years, with the latest figure at -$12000.0 for Q3 2023.

  • For Q3 2023, Amortizatization of Intangibles rose 88.12% year-over-year to -$12000.0; the TTM value through Jun 2024 reached -$12000.0, up 97.79%, while the annual FY2023 figure was -$234000.0, 27.1% up from the prior year.
  • Amortizatization of Intangibles for Q3 2023 was -$12000.0 at Cue Biopharma, up from -$73000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $3.0 million in Q4 2021 and bottomed at -$220000.0 in Q4 2022.
  • The 4-year median for Amortizatization of Intangibles is -$12000.0 (2023), against an average of $278815.7.
  • The largest annual shift saw Amortizatization of Intangibles surged 45323.47% in 2021 before it tumbled 107.24% in 2022.
  • A 4-year view of Amortizatization of Intangibles shows it stood at $6694.0 in 2020, then soared by 45323.47% to $3.0 million in 2021, then crashed by 107.24% to -$220000.0 in 2022, then soared by 94.55% to -$12000.0 in 2023.
  • Per Business Quant, the three most recent readings for CUE's Amortizatization of Intangibles are -$12000.0 (Q3 2023), -$73000.0 (Q2 2023), and -$149000.0 (Q1 2023).